1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

AryoGen Bevacizumab Biosimilar Compares To Avastin

Iranian Player Has Ambitions In Biotech Space

 
• By Dean Rudge

Iranian player AryoGen has received a boost after a recent study revealed that the firm’s bevacizumab biosimilar was non-inferior to reference product Avastin terms of efficacy and tolerability.

Azadi_Tower_Iran
Tehran-based AryoGen has received a boost for bevacizumab • Source: Shutterstock

AryoGen Pharmed’s BE1040V biosimilar bevacizumab candidate has demonstrated comparable efficacy and tolerability to Genentech’s reference product, Avastin, according to the results of a Phase III clinical study in patients with metastatic colorectal cancer published in Clinical Therapeutics.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.